Thus, if the treatment does not yield a reduction in tumor size shortly after the start of treatment, it may be advantageous to administer an IL-2 immunotherapy in combination with the OVT and anti-PD-1, in order to increase the T cell proliferation rate. This evidence concerns the gene IL2 and neoplasm.